The SBI Healthcare Opportunities Fund delivered a 6% return over the past month, outpacing peers and its benchmark. While sectoral funds offer targeted exposure, their performance remains closely linked to the volatility of the pharmaceutical and healthcare industry.
The SBI Healthcare Opportunities Fund has emerged as the top performer among dedicated pharmaceutical and healthcare sectoral mutual funds, recording a 6% return over a recent one-month period. Data as of July 7, 2026, for funds with assets under management exceeding ₹1,500 crore, indicates that this return surpassed competitors such as the ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund and the DSP Healthcare Fund, both of which posted returns of 5.8% during the same timeframe.
Benchmark and Performance Comparison
A key driver of this performance has been the fund’s ability to outpace its designated benchmark index. While the benchmark returned 0% over the one-month period, the SBI Healthcare Opportunities Fund achieved a 6% gain. This trend of outperformance is also visible over a longer investment horizon. Over the past year, the fund beat its benchmark by 8.6 percentage points, even as the benchmark itself managed a return of 4.4%. However, it is worth noting that performance leadership is not static; for instance, the Mirae Asset Healthcare Fund secured the highest return among the top five schemes over a one-year period at 13.7%, while the ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund led the three-year category with a 25.3% gain.
Sectoral Risks for Investors
Investors looking at sectoral funds must account for the inherent risks associated with this investment structure. Unlike diversified mutual funds that spread risk across multiple industries, sectoral funds concentrate their capital within a single business area. This focus means that the fund’s returns are entirely dependent on the growth, regulatory environment, and pricing trends of the pharmaceutical and healthcare sector. If the sector faces pressure—such as increased price controls, supply chain disruptions, or regulatory changes in export markets—the fund's value can experience higher volatility compared to broader market indices.
Before investing, individuals should consider that sectoral funds are generally recommended for those with a higher risk appetite and a specific investment thesis regarding the healthcare industry. The performance of these funds is often cyclical, and past gains over short periods like one month or six months do not guarantee future results. Investors should monitor the fund’s long-term consistency, the quality of its underlying stock holdings, and the overall health of the Indian pharma sector when assessing these investment options.